Amgen

Open: 284.84 Close: 283.46 Change: -1.38

Stop reading the whole internet to decide if you want to invest in Amgen Company Inc.

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen (AMGN) reported Q4 2023 earnings per share (EPS) of $1.42 , missing estimates of $4.59 by 69.06%. Amgen is letting go of 350 employees following its $27.8 billion acquisition of Horizon Therapeutics.

Today's News

Amgen inc. stock underperforms wed Wednesday when compared to competitors - marketwatch.com. Amgen Inc. (amgn) stock news | stock titan. Amgen continues its sponsorship of the Irish Open following the acquisition of Horizon Therapeutics plc. The 2024 Amgen Irish Open will take place at the Royal County Down Golf Club in Northern Ireland. Amgen (NASDAQ:AMGN) will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, Murdo Gordon, executive. vice. president of Global Commercial Operations at Amen, executive VP of Global Commerical Operations at. Amgen. Presentations: The technology slippingova deficit loos Bookrily0010Onlineaudi EXP Scientology Amgen is letting go of 350 employees following its $27.8 billion acquisition of Horizon Therapeutics. This is Amgens third round of layoffs this year. Jean-Charles Soria, MD, PhD posted on the topic. The FDA approved 55 novel therapeutics in 2023. Amgen is an Equal Opportunity Employer and will consider applicants without regard to race, color, religion, sex, sexual orientation, national origin, protected veteran status, or disability status. Amgen is a U.S.-based multinational biopharmaceutical company, headquartered in Thousand Oaks, California. Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Statistics on Amgen The most important statistics Total worldwide prescription drug revenue - projection 2020-2028 Percentage of global pharmaceutical sales by technology. Top global biotech companies based on number of employees 2023 Sales per employee of select U.S. biotech and drugs companies Q3 2023 AI readiness of big pharma. Amgen (AMGN) reported Q4 2023 earnings per share (EPS) of $1.42 , missing estimates of $4.59 by 69.06%. Amgen is expected to release next earnings on 05/02/2024 with an earnings per quarter estimate of $3.00. Amgen Inc. (AMGN) Stock Price, Quote & News - Stock Analysis. Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science. Amgen will present at the 34th Annual Oppenheimer Healthcare Life Sciences Conference at 12:00 p.m. on February 9, 2024. Amgen announced financial results for the fourth quarter and full year 2023 versus comparable periods in 2022. Amgen shareholders who owned Amgen shares before Feb 15, 2024 received a dividend payment of $2.25 per share. Amgens past year earnings per share was $12.48, and annual dividend per share is $8.64. Amgen stock price | amgn stock quote, news, and history | markets insider. amgen stock. market capitalization is $151.94 B by 535.92 M shares outstanding.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, share, earnings, executive, employee, year, and the most common words in the summary are: amgen, stock, market, report, overview, data, clinical, . One of the sentences in the summary was: Amgen (AMGN) reported Q4 2023 earnings per share (EPS) of $1.42 , missing estimates of $4.59 by 69.06%. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #report #overview #data #clinical.